Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

barecetamab (ISU104)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

ISU Abxis

Drug class:

HER3 inhibitor

Related drugs:

EGFR mutation	Squamous Cell Carcinoma of Head and Neck	EGFR mutation	Squamous Cell Carcinoma of Head and Neck	cetuximab + ISU104 Sensitive: C3 – Early Trials cetuximab + ISU104 Sensitive : C3	cetuximab + ISU104 Sensitive: C3 – Early Trials cetuximab + ISU104 Sensitive : C3
NRG1 mutation	Squamous Cell Carcinoma of Head and Neck	NRG1 mutation	Squamous Cell Carcinoma of Head and Neck	cetuximab + ISU104 Sensitive: C3 – Early Trials cetuximab + ISU104 Sensitive : C3	cetuximab + ISU104 Sensitive: C3 – Early Trials cetuximab + ISU104 Sensitive : C3
HER-2 mutation	Squamous Cell Carcinoma of Head and Neck	HER-2 mutation	Squamous Cell Carcinoma of Head and Neck	cetuximab + ISU104 Sensitive: C3 – Early Trials cetuximab + ISU104 Sensitive : C3	cetuximab + ISU104 Sensitive: C3 – Early Trials cetuximab + ISU104 Sensitive : C3
ERBB3 mutation	Squamous Cell Carcinoma of Head and Neck	ERBB3 mutation	Squamous Cell Carcinoma of Head and Neck	cetuximab + ISU104 Sensitive: C3 – Early Trials cetuximab + ISU104 Sensitive : C3	cetuximab + ISU104 Sensitive: C3 – Early Trials cetuximab + ISU104 Sensitive : C3